<p>Adam Dingens is the platform lead at Apriori Bio. He leverages expertise in virology and functional genomics to develop novel technologies that unlock new paradigms in vaccine design. Previously, Adam built AAV engineering technologies at Shape Therapeutics, and was a graduate student fellow and staff scientist in the labs of Jesse Bloom and Julie Overbaugh at the Fred Hutch. There, he obtained a PhD in molecular and cellular biology and an MS in epidemiology from the University of Washington and received awards such as the Gates Foundation’s Norm Letvin Early Career Investigator, the Hal Weintraub Graduate Student award, an NSF Graduate Research Fellowship, and an NIH T32 training grant. Adam’s work has yielded 30+ publications and pending patent applications, including articles in Science, Nature, Cell, etc.</p>

large_Dingens_Final_1.jpg

Adam Dingens, PhD

Platform Lead, Apriori Bio